30 terminated. 30 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 30 | Terminated 30 |
| Phase 2 | 3 | Terminated 3 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial SerpinPC - Hemophilia a, Hemophilia B | Phase 3 | Terminated | ApcinteX Ltd | 15 | 2024-07-11 | 2025-02-10 |
| Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery Coagulation Factor VIIa (Recombinant) - Hemophilia | Phase 3 | Terminated | Laboratoire français de Fractionnement et de Biotechnologies | 2 | 2024-06-07 | 2026-07-31 |
| The Hemophilia Inhibitor Eradication Trial Eloctate ITI, Emicizumab - Hemophilia A With Inhibitor | Phase 3 | Terminated | Margaret Ragni | 1 | 2021-11-01 | 2023-02-21 |
| The Hemophilia Inhibitor Prevention Trial Eloctate Injectable Product, Emicizumab Injection [Hemlibra] - Hemophilia A Without Inhibitor | Phase 3 | Terminated | Margaret Ragni | 1 | 2021-10-11 | 2023-04-11 |
| Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy TRM-201 (Rofecoxib), Placebo - Hemophilic Arthropathy | Phase 3 | Terminated | Tremeau Pharmceuticals, Inc. | 2 | 2021-06-02 | 2022-10-27 |
| A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Rozanolixizumab - Primary Immune Thrombocytopenia | Phase 3 | Terminated | UCB Biopharma SRL | 43 | 2021-01-06 | 2024-02-05 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Rozanolixizumab, Placebo - Primary Immune Thrombocytopenia | Phase 3 | Terminated | UCB Biopharma SRL | 30 | 2020-06-03 | 2023-08-08 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Rozanolixizumab, Placebo - Primary Immune Thrombocytopenia | Phase 3 | Terminated | UCB Biopharma SRL | 33 | 2020-01-31 | 2025-03-18 |
| Minimize Menorrhagia in Women With Von Willebrand Disease recombinant von Willebrand factor, tranexamic acid - Von Willebrand Diseases | Phase 3 | Terminated | Margaret Ragni | 39 | 2019-02-07 | 2024-07-01 |
| Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial Turoctocog alfa - Haemophilia A | Phase 3 | Terminated | Novo Nordisk A/S | 1 | 2018-06-12 | 2020-07-07 |
| The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα - Essential Thrombocythemia | Phase 2 / Phase 3 | Terminated | French Innovative Leukemia Organisation | 13 | 2017-01-03 | 2021-06-29 |
| BAX 802 in CHA With Inhibitors Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802) - Hemophilia A | Phase 3 | Terminated | Baxalta now part of Shire | 8 | 2016-12-22 | 2021-10-20 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 311 | 2014-02-01 | 2021-11-18 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 327 | 2013-01-01 | 2020-09-29 |
| Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development Biostate - Hemophilia A | Phase 3 | Terminated | CSL Behring | 1 | 2012-12-01 | 2017-10-03 |
| Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A rF.VIII - Severe Hemophilia A | Phase 3 | Terminated | University of Pittsburgh | 4 | 2012-07-01 | 2016-10-07 |
| A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) Eltrombopag, Avatrombopag, Standard of care - Idiopathic Thrombocytopenic Purpura | Phase 3 | Terminated | Eisai Inc. | 24 | 2012-03-26 | 2018-02-06 |
| A Phase 3 Clinical Study of KW-3357 in Patients With DIC KW-3357 - Disseminated Intravascular Coagulation (DIC) | Phase 3 | Terminated | Kyowa Kirin Co., Ltd. | 5 | 2012-02-01 | 2017-03-24 |
| Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A OBI-1 - Hemophilia A | Phase 3 | Terminated | Baxalta now part of Shire | 1 | 2011-10-03 | 2021-05-14 |
| Early Prophylaxis Immunologic Challenge (EPIC) Study Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM) - Hemophilia A | Phase 3 | Terminated | Baxalta now part of Shire | 22 | 2011-08-26 | 2021-05-24 |
Showing 20 of 30. Sign in to see all of them.
Hemophilia A (14) · Purpura, Thrombocytopenic, Idiopathic (5) · Hematologic Diseases (4) · Hemostatic Disorders (3) · Thrombocythemia, Essential (3) · von Willebrand Diseases (3) · Anemia (2) · Bone Marrow Diseases (2) · Hemophilia B (2) · Hemorrhagic Disorders (2) · Myeloproliferative Disorders (2) · Polycythemia Vera (2) · Primary Myelofibrosis (2) · Purpura, Thrombotic Thrombocytopenic (2) · Splenomegaly (2)
Hemic and Lymphatic Diseases (30) · Hemorrhagic Disorders (27) · Hematologic Diseases (26) · Blood Coagulation Disorders, Inherited (19) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (19) · Genetic Diseases, Inborn (19) · Coagulation Protein Disorders (17) · Blood Platelet Disorders (13) · Pathological Conditions, Signs and Symptoms (11) · Cytopenia (9) · Hemorrhage (8) · Pathologic Processes (8) · Signs and Symptoms (8) · Purpura (7)
Factor VIII (3) · rozanolixizumab (3) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Adrenal Cortex Hormones (2) · Prednisone (2) · Rituximab (2) · emicizumab (2) · factor VIII-Fc fusion protein (2) · optivate (2) · Factor VII (1) · Factor X (1) · IB1001 (1) · Plasma Exchange (1) · Protein C (1) · Solvents (1)
Baxalta now part of Shire (3) · Bio Products Laboratory (3) · Margaret Ragni (3) · UCB Biopharma SRL (3) · CTI BioPharma (2) · Carelon Research (2) · ApcinteX Ltd (1) · CSL Behring (1) · Eisai Inc. (1) · French Innovative Leukemia Organisation (1) · Georgetown University (1) · Instituto Grifols, S.A. (1) · Kyowa Kirin Co., Ltd. (1) · Laboratoire français de Fractionnement et de Biotechnologies (1) · Medexus Pharma, Inc. (1)
United States (20) · United Kingdom (11) · Germany (8) · Russia (8) · France (6) · Italy (6) · Poland (6) · Spain (6) · Bulgaria (5) · Turkey (Türkiye) (5) · Canada (4) · Hungary (4) · Netherlands (4) · Ukraine (4) · Australia (3)
Margaret V Ragni, MD, MPH (3) · Cindy Leissinger, MD (2) · David Kuter, MD (2) · Ellis Neufeld, MD (2) · James Bussel, MD (2) · James George, MD (2) · Joseph Kiss, MD (2) · Thomas Ortel, MD (2) · Alvin Schmaier, MD (1) · Ann Zimrin, MD (1) · Barbara Konkle, MD (1) · Beth Ziemba (1) · Bruce Sachais, MD, PhD (1)
PMID 33275766, PMID 25912619, PMID 34551507, PMID 37385272, PMID 39400386, PMID 39552477, PMID 42316774
2019 (3), U01HL072268 (2), 2015 (1), 2016 (1), 2023 (1), R34HL105870 (1), U01HL133815 (1)